by Graft-versus-host disease (GvHD), a common complication following hematopoietic stem cell transplantation, occurs when the donor’s immune cells attack the recipient’s tissues. This condition can lead to severe health issues and even death. However, recent research suggests a promising solution using immunosuppressive induced pluripotent stem cell-derived regulatory T cells (iPS-Tregs).
According to a recent study published in the journal Nature Communications, researchers from the University of California, San Diego School of Medicine have successfully generated iPS-Tregs that can suppress the Immune Cells response responsible for GvHD. These Tregs were created by reprogramming donor cells into iPS cells and then differentiating them into Tregs.
The team found that these iPS-Tregs were more potent than naturally occurring Tregs in suppressing the immune response in mice with GvHD. Moreover, they were able to prevent the development of GvHD symptoms in the animals.
The researchers believe that this approach could potentially be used to prevent or treat GvHD in human patients undergoing hematopoietic stem cell transplantation. They plan to conduct further studies to evaluate the safety and efficacy of iPS-Tregs in clinical trials.
The use of immunosuppressive iPS cell-derived regulatory T cells shows great promise in overcoming graft-versus-host disease, a significant challenge in hematopoietic stem cell transplantation. The successful generation and suppression of the immune response in mice with GvHD brings us one step closer to a potential breakthrough in this field.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
